Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter

NCT01753232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2015-09-04

No results posted yet for this study

Summary

Low Density Lipoprotein (LDL)-apheresis refers to a procedure in which blood taken from a patient's vein is cleaned from pathogenic substances, e.g. cholesterol, outside the body and then given back to the patient. In the DALI (Direct Adsorption of Lipoproteins)-system whole blood is pumped over an adsorber containing beads that selectively bind LDL-cholesterol. The MONET (Membrane filtration Optimized Novel Extracorporeal Treatment)-system works with plasma which is cleaned by filtration. This study comprises the recording of safety and efficacy data from patients treated either with the DALI or MONET-system over a period of 2 years.

Conditions

  • Hypercholesterolemia, Familial
  • LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA

Interventions

DEVICE

DALI-adsorber

Recording of treatment data. No extra interventional treatment

DEVICE

MONET-Lipoprotein filter

Only treatment data recording. No extra interventional treatment

Sponsors & Collaborators

  • Fresenius Medical Care Deutschland GmbH

    lead INDUSTRY

Principal Investigators

  • Rainer Heinzler, MD · Gemeinschaftspraxis Gysan, Heinzler, May, Hossmann

  • Franz Heigl, MD · Dres. Heigl, Hettich & Partner Medizinisches Versorgungszentrum

  • Frank Leistikow, MD · Nierenzentrum Mannheim

  • Frido Himmelsbach, MD · Apheresezentrum Ingelheim

  • Ralf Spitthöver, MD · Nephrologische Gemeinschaftspraxis Dialysezentrum/Lipidzentrum

  • Eberhard Roeseler, MD, Prof · Zentrum für Nieren,- Hochdruck und Stoffwechselerkrankungen Standort Heidering

  • Volker Schettler, MD · Nephrologisches Zentrum Goettingen

  • Gerd Schmitz, MD, Prof · University Regensburg Department Clinical Chemistry and Laboratory Medicine

  • Nadim Abduhl-Rahman, MD · Dialysezentrum Magdeburg-Stadtfeld

  • Jens Ringel, MD · Dialysezentrum Potsdam

  • Wolfgang Ramlow, MD · Apheresezentrum Rostock

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-12-31
Completion
2015-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01753232 on ClinicalTrials.gov